GlassScriptPhysician profile
Brett Michael Wertman
NPI 1043349772
$6,427.76
in general payments reported to CMS, 2019-2025
31 companies · $1,144 in 2025
The $1,144 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,021 · 2020: $833 · 2021: $723 · 2022: $955 · 2023: $817 · 2024: $935 · 2025: $1,144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,896.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,896.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $3,115.17 | 2019-2025 | Orsiro Mission, Biomonitor, Acticor 7 Vr-T Dx |
| Novartis Pharmaceuticals Corporation | $567.21 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $279.64 | 2023-2025 | Jardiance |
| Amgen INC. | $235.10 | 2022-2025 | Repatha, Repatha |
| Atricure, INC. | $198.40 | 2022-2024 | |
| Astellas Pharma US INC | $198.00 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $172.92 | 2023-2025 | Farxiga, Wainua |
| Pfizer INC. | $166.70 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $156.49 | 2022-2025 | |
| Boston Scientific Corporation | $155.33 | 2019-2024 | Watchman Flx |
| Aop Health US, LLC | $140.00 | 2025 | Rapiblyk |
| E.R. Squibb & Sons, L.L.C. | $133.30 | 2023-2025 | Eliquis, Camzyos |
| Medtronic Vascular, INC. | $130.67 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $95.13 | 2023-2024 | |
| Edwards Lifesciences Corporation | $93.07 | 2021-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $75.39 | 2025 | Wegovy |
| Merck Sharp & Dohme LLC | $67.26 | 2023-2024 | Verquvo |
| Kiniksa Pharmaceuticals, LTD. | $50.41 | 2023 | Arcalyst |
| Medtronic, INC. | $46.47 | 2022 | |
| Scpharmaceuticals INC. | $44.02 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $43.62 | 2023-2025 | Lifevest |
| Abbott Laboratories | $37.21 | 2019-2024 | Mitraclip |
| Abiomed | $36.96 | 2024 | Impella |
| Janssen Pharmaceuticals, INC | $33.87 | 2024 | Xarelto |
| Altathera Pharmaceuticals LLC | $28.27 | 2025 | Sotalol Hydrochloride |
| Impulse Dynamics (USA) INC. | $26.02 | 2025 | Optimizer |
| Lilly USA, LLC | $23.01 | 2025 | Zepbound, Mounjaro |
| Lexicon Pharmaceuticals, INC. | $22.28 | 2024 | |
| Esperion Therapeutics, INC. | $21.42 | 2025 | Nexletol |
| Kiniksa Pharmaceuticals International, Plc | $18.39 | 2024 | Arcalyst |
| Kestra Medical Technology Services, INC. | $16.03 | 2025 | Assure Wcd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brett Wertman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.